| Literature DB >> 30025992 |
Xiaoguang Zhao1, Jian Sun1, Yingzhun Chen2, Wei Su1, Huitong Shan1, Yue Li1, Yining Wang1, Nan Zheng3, Hongli Shan4, Haihai Liang5.
Abstract
Long non-coding RNAs (lncRNAs) have been reported to be involved in various pathophysiological processes in many diseases. However, the role and mechanism of lncRNAs in idiopathic pulmonary fibrosis (IPF) have not been explicitly delineated. In the present study, we reported that lncRNA NONMMUT065582, designated pulmonary fibrosis-associated RNA (PFAR), is upregulated in the lungs of mice with lung fibrosis as well as in fibrotic lung fibroblasts. Overexpression of PFAR promoted fibrogenesis through modulation of miR-138, whereas knockdown of PFAR attenuated TGF-β1-induced fibrogenesis in lung fibroblasts. In addition, knockdown of miR-138 promoted fibrogenesis by targeting regulation of yes-associated protein 1 (YAP1), whereas enhanced expression of miR-138 attenuated fibrogenesis in lung fibroblasts. Mechanistically, PFAR acted as competing endogenous RNA (ceRNA) of miR-138: forced expression of PFAR reduced the expression and activity of miR-138 to activate YAP1 and promote fibrogenesis in lung fibroblasts, whereas loss of YAP1 abrogated the pro-fibrotic effect of PFAR. More importantly, PFAR silencing alleviated BLM-induced lung fibrosis in mice. Taken together, the results of our study identified lncRNA PFAR as a new pro-fibrotic molecule that acts as a ceRNA of miR-138 during lung fibrosis and demonstrated PFAR as a novel therapeutic target for the prevention and treatment of lung fibrosis.Entities:
Keywords: Twist; YAP1; idiopathic pulmonary fibrosis; lncRNA PFAR; miR-138
Mesh:
Substances:
Year: 2018 PMID: 30025992 PMCID: PMC6127506 DOI: 10.1016/j.ymthe.2018.06.020
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454